Works Cited

Pancreatic Cancer

Course #90240 - $60 • 10 Hours/Credits

  • Back to Course Home
  • Participation Instructions
    • Review the course material online or in print.
    • Complete the course evaluation.
    • Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.

1. Hall BR, Cannon A, Atri P, et al. Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. Oncotarget. 2018;9:19396-19405.

2. Grossberg AJ, Chu LC, Deig CR, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin. 2020;70:375-403.

3. Lei F, Xi X, Batra SK, et al. Combination therapies and drug delivery platforms in combating pancreatic cancer. J Pharmacol Exp Ther. 2019;370(3):682-694.

4. Ciernikova S, Earl J, García Bermejo ML, et al. Epigenetic landscape in pancreatic ductal adenocarcinoma: on the way to overcoming drug resistance? Int J Mol Sci. 2020;21(11):4091.

5. Kato H, Horiguchi A, Ito M, et al. Multimodal treatment of localized pancreatic adenocarcinoma: current topics and updates in survival outcomes and prognostic factors. Ann Gastroenterol Surg. 2021;5:132-151.

6. Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(21):2541-2556.

7. Khorana AA, McKernin SE, Berlin J, et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. J Clin Oncol. 2019;37:2082-2088.

8. Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(22):2654-2668.

9. Sohal DPS, Mangu PB, Khorana AA, et al. Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(23):2784-2796.

10. Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. 2020;38(27):3217-3230.

11. Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(4):439-457.

12. Palta M, Godfrey D, Goodman KA, et al. Radiation therapy for pancreatic cancer: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2019;9(5):322-332.

13. Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v56-v68.

14. European Society of Medical Oncology. eUpdate: Cancer of the Pancreas Treatment Recommendations. Available at Last accessed July 14, 2021.

15. National Institute for Health and Care Excellence. Pancreatic Cancer in Adults: Diagnosis and Management. Available at Last accessed August 13, 2021.

16. Martin-Perez E, Domínguez-Muñoz JE, Botella-Romero F, et al. Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer. Clin Transl Oncol. 2020;22(11):1963-1975.

17. Iacobuzio-Donahue CA. Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut. 2012;61(7):1085-1094.

18. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33.

19. National Cancer Institute. Cancer Stat Facts: Pancreatic Cancer. Available at Last accessed August 13, 2021.

20. Khoudari G, Alkhayyat M, Abou Saleh M, et al. The epidemiology of pancreatic cancer and the association with acetylsalicylic acid in the United States: a population-based study. Pancreas. 2020;49(9):1207-1212.

21. Tian C, Clauser KR, Öhlund D, et al. Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proc Natl Acad Sci U S A. 2019;116(39):19609-19618.

22. Heller DR, Nicolson NG, Ahuja N, et al. Association of treatment inequity and ancestry with pancreatic ductal adenocarcinoma survival. JAMA Surg. 2020;155:e195047.

23. Noel M, Fiscella K. Disparities in pancreatic cancer treatment and outcomes. Health Equity. 2019;3(1):532-540.

24. Dragovich T. Pancreatic Cancer. Available at Last accessed July 14, 2021.

25. Duell EJ, Holly EA, Bracci PM, et al. A population-based, case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk. J Natl Cancer Inst. 2002;94(4):297-306.

26. Fernandez-del Castillo C, Jimenez RE. Epidemiology and Nonfamilial Risk Factors for Exocrine Pancreatic Cancer. Available at Last accessed July 14, 2021.

27. Korc M, Jeon CY, Edderkaoui M, et al. Tobacco and alcohol as risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2017;31(5):529-536.

28. Genkinger JM, Kitahara CM, Bernstein L, et al. Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies. Ann Oncol. 2015;26:2257-2266.

29. Abbruzzese JL, Andersen DK, Borrebaeck CAK, et al. The interface of pancreatic cancer with diabetes, obesity, and inflammation: research gaps and opportunities. Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. Pancreas. 2018;47(5):516-525.

30. Nkondjock A, Ghadirian P, Johnson KC, Krewski D. Dietary intake of lycopene is associated with reduced pancreatic cancer risk.J Nutr. 2005;135(3):592-597.

31. Waterhouse M, Risch HA, Bosetti C, et al. Vitamin D and pancreatic cancer: a pooled analysis from the pancreatic cancer case-control consortium. Ann Oncol. 2015;26(8):1776-1783.

32. Borazanci E, Dang CV, Robey RW, et al. Pancreatic cancer: "a riddle wrapped in a mystery inside an enigma." Clin Cancer Res. 2017;23:1629-1637.

33. Maisonneuve P, Amar S, Lowenfels AB. Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis. Ann Oncol. 2017;28:985-995.

34. Hoare A, Soto C, Rojas-Celis V, Bravo D. Chronic inflammation as a link between periodontitis and carcinogenesis. Mediators Inflamm. 2019;2019:1029857.

35. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993;328(20):1433-1437

36. Kim NH, Chang Y, Lee SR, et al. Glycemic status, insulin resistance, and risk of pancreatic cancer mortality in individuals with and without diabetes. Am J Gastroenterol. 2020;115(11):1840-1848.

37. Sah RP, Nagpal SJS, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol. 2013;10(7):423-433.

38. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, et al. Type II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92:2076-2083.

39. Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer. 2011;47:1928-1937.

40. Grote VA, et al. Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Diabetologia. 2011;54:3037-3046.

41. Ogawa Y, et al. A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer. 2002;94:2344-2349.

42. Cho J, Scragg R, Pandol SJ, et al. Antidiabetic medications and mortality risk in individuals with pancreatic cancer-related diabetes and postpancreatitis diabetes: a nationwide cohort study. Diabetes Care. 2019;42:1675-1683.

43. Sadeghi N, Abbruzzese JL, Yeung SCJ, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res. 2012;18(10):2905-2912.

44. Chaiteerakij R, Petersen GM, Bamlet WR, et al. Metformin use and survival of patients with pancreatic cancer: a cautionary lesson. J Clin Oncol. 2016;34:1898-1904.

45. Toriola AT, Stolzenberg-Solomon R, Dalidowitz L, Linehan D, Colditz G. Diabetes and pancreatic cancer survival: a prospective cohort-based study. Br J Cancer. 2014;111(1):181-185.

46. Sah RP, Sharma A, Nagpal S, et al. Phases of metabolic and soft tissue changes in months preceding a diagnosis of pancreatic ductal adenocarcinoma. Gastroenterology. 2019;156(6):1742-1752.

47. Liao WC, Chen PR, Huang CC, et al. Relationship between pancreatic cancer-associated diabetes and cachexia. J Cachexia Sarcopenia Muscle. 2020;11(4):899-908.

48. Felsenstein M, Hruban RH, Wood LD. New developments in the molecular mechanisms of pancreatic tumorigenesis. Adv Anat Pathol. 2018;25:131-142.

49. Hruban RH. Molecular Pathogenesis of Exocrine Pancreatic Cancer. Available at Last accessed August 13, 2021.

50. Mortoglou M, Tabin ZK, Arisan ED, et al. Non-coding RNAs in pancreatic ductal adenocarcinoma: new approaches for better diagnosis and therapy. Transl Oncol. 2021;14(7):101090.

51. Evan GI, Hah N, Littlewood TD, et al. Re-engineering the pancreas tumor microenvironment: a "regenerative program" hacked. Clin Cancer Res. 2017;23(7):1647-1655.

52. Rodríguez Gil Y, Jiménez Sánchez P, Muñoz Velasco R, García García A, Sánchez-Arévalo Lobo VJ. Molecular alterations in pancreatic cancer: transfer to the clinic. Int J Mol Sci. 2021;22(4):2077.

53. Riva G, Pea A, Pilati C, et al. Histo-molecular oncogenesis of pancreatic cancer: from precancerous lesions to invasive ductal adenocarcinoma. World J Gastrointest Oncol. 2018;10(10):317-327.

54. Morani AC, Hanafy AK, Ramani NS, et al. Hereditary and sporadic pancreatic ductal adenocarcinoma: current update on genetics and imaging. Radiol Imaging Cancer. 2020;2(2):e190020.

55. Daly MB, Pal TP, Berry MP, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021. J Natl Compr Canc Netw. 2021;19:77-102.

56. Connor AA, Denroche RE, Jang GH, et al. Integration of genomic and transcriptional features in pancreatic cancer reveals increased cell cycle progression in metastases. Cancer Cell. 2019;35(2):267-282.

57. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol. 2001;25(5):579-586.

58. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6(8):2969-2972.

59. Parkin AA, Man J, Chou A, et al. The evolving understanding of the molecular and therapeutic landscape of pancreatic ductal adenocarcinoma. Diseases. 2018;6:103.

60. Hanada K, Amano H, Abe T. Early diagnosis of pancreatic cancer: current trends and concerns. Ann Gastroenterol Surg. 2017; 1:44-51.

61. Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011;144(1):27-40.

62. Dreyer SB, Chang DK, Bailey P, Biankin AV. Pancreatic cancer genomes: implications for clinical management and therapeutic development. Clin Cancer Res. 2017;23(7):1638-1646.

63. Notta F, Chan-Seng-Yue M, Lemire M, et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature. 2016;538(7625):378-382.

64. Chan-Seng-Yue M, Kim JC, Wilson GW, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet. 2020;52(2):231-240.

65. Pompella L, Tirino G, Pappalardo A, et al. Pancreatic cancer molecular classifications: from bulk genomics to single cell analysis. Int J Mol Sci. 2020;21(8):2814.

66. Iovanna J. Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer. Translational Oncology. 2021;14:100965.

67. Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017;32(2):185-203.

68. Barcellini A, Peloso A, Pugliese L, et al. Locally advanced pancreatic ductal adenocarcinoma: challenges and progress. Onco Targets and Therapy. 2020;13:12705-12720.

69. Vennin C, Murphy KJ, Morton JP, Cox TR, Pajic M, Timpson P. Reshaping the tumor stroma for treatment of pancreatic cancer. Gastroenterology. 2018;154(4):820-838.

70. Canto MI. Familial Risk Factors for Pancreatic Cancer and Screening of High-Risk Patients. Available at Last accessed July 14, 2021.

71. Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69:7.

72. Earl J, Galindo-Pumariño C, Encinas J, et al. A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants. EBioMedicine. 2020;53:102675.

73. Stoffel EM, McKernin SE, Brand R, et al. Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion.J Clin Oncol. 2019; 37(2):153-164.

74. U.S. Preventive Services Task Force, Owens DK, Davidson KW, et al. Screening for pancreatic cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2019;322(5):438-444.

75. McGuigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846-4861.

76. Mills K, Birt L, Emery JD, et al. Understanding symptom appraisal and help-seeking in people with symptoms suggestive of pancreatic cancer: a qualitative study. BMJ Open. 2017;7(9):e015682.

77. Keane MG, Horsfall L, Rait G, Pereira SP. A case-control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer. BMJ Open. 2014;4(11):e005720.

78. Shindo K, Yu J, Suenaga M, et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol. 2017;35(30):3382-3390.

79. Ryan DP, Mamon H. Initial Chemotherapy and fadiation For Nonmetastatic, Locally Advanced, Unresectable and Borderline Resectable, Exocrine Pancreatic Cancer. Available at Last accessed July 20, 2021.

80. Ryan DP. Initial Systemic Chemotherapy for Metastatic Exocrine Pancreatic Cancer. Available at Last accessed July 20, 2021.

81. Nguyen M. Pancreatic cancer. In: Merck Manual Professional Version. Kenilworth, NJ: Merck Sharp & Dohme Corp; 2021.

82. Porta M, Fabregat X, Malats N, et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol. 2005;7(5):189-197.

83. Turaga KK, Malafa MP, Jacobsen PB, Schell M, Sarr MG. Suicide in patients with pancreatic cancer. Cancer. 2011;117(3):642-647.

84. Fernandez-del Castillo C. Clinical Manifestations, Diagnosis, and Staging of Exocrine Pancreatic Cancer. Available at Last accessed August 13, 2021.

85. Puckett Y, Garfield K. Pancreatic Cancer. Available at Last accessed July 19, 2021.

86. Kordes M, Larsson L, Engstrand L, Löhr JM. Pancreatic cancer cachexia: three dimensions of a complex syndrome. Br J Cancer. 2021;124(10):1623-1636.

87. Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Gastroenterology. 2014;146:291-304.

88. Tummers WS, Willmann JK, Bonsing BA, Vahrmeijer AL, Gambhir SS, Swijnenburg RJ. Advances in diagnostic and intraoperative molecular imaging of pancreatic cancer. Pancreas. 2018;47(6):675-689.

89. Al-Hawary M. Role of imaging in diagnosing and staging pancreatic cancer. J Natl Compr Canc Netw. 2016;14(5.5):678-680.

90. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. Journal of Gastrointestinal Oncology. 2012;3:105-120.

91. Giannis D, Moris D, Barbas AS. Diagnostic, predictive and prognostic molecular biomarkers in pancreatic cancer: an overview for clinicians. Cancers. 2021;13:1071.

92. Zhao B, Cheng Q, Cao H, et al. Dynamic change of serum CA19-9 levels in benign and malignant patients with obstructive jaundice after biliary drainage and new correction formulas. BMC Cancer. 2021;21:517.

93. Kakar S, Pawlik TM, Allen PJ, et al. Exocrine pancreas. In: Amin MB (ed). AJCC Cancer Staging Manual. 8th ed. Chicago, IL: American Joint Committee on Cancer; 2017.

94. Chawla A, Wo J, Castillo CF, et al. Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. Pancreatology. 2020;20(4):691-697.

95. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:1039-1049.

96. Elsayed M, Abdelrahim M. The latest advancement in pancreatic ductal adenocarcinoma therapy: a review article for the latest guidelines and novel therapies. Biomedicines. 2021;9:389.

97. Neeman E, Gresham G, Ovasapians N, et al. Comparing physician and nurse Eastern Cooperative Oncology Group performance status (ECOG-PS) ratings as predictors of clinical outcomes in patients with cancer. Oncologist. 2019;24:e1460-e1466.

98. Ryan DP, Mamon H. Treatment for Potentially Resectable Exocrine Pancreatic Cancer. Available at Last accessed July 20, 2021.

99. National Cancer Institute. Pancreatic Cancer: Health Professional Version. Available at Last accessed August 13, 2021.

100. Torgeson A, Garrido-Laguna I, Tao R, Cannon GM, Scaife CL, Lloyd S. Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. ESMO Open. 2018;3(1):e000282.

101. Cellini F, Arcelli A, Simoni N, et al. Basics and frontiers on pancreatic cancer for radiation oncology: target delineation, SBRT, SIB technique, MRgRT, particle therapy, immunotherapy and clinical guidelines. Cancers (Basel). 2020;12(7):1729.

102. Fernandez-del Castillo C, Jimenez RE. Overview of Surgery in the Treatment of Exocrine Pancreatic Cancer and Prognosis. Available at Last accessed August 11, 2021.

103. Winter JM, Brennan MF, Tang LH, et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol. 2012;19(1):169-175.

104. Bengtsson A, Andersson R, Ansari D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data.Sci Rep. 2020;10(1):16425.

105. Brenner T, Duggal S, Natale J, Goldberg RM. Treatment Protocols for Pancreatic Cancer. Available at Last accessed July 14, 2021.

106. Ryan DP. Second-Line Systemic Therapy for Advanced Exocrine Pancreatic Cancer. Available at Last accessed July 20, 2021.

107. The Medical Letter. In brief: pembrolizumab (Keytruda) for cancers with biomarkers. Med Lett Drugs Ther. 2018;60(1537):e8.

108. Golan T, Hammel P. Management of BRCA mutation carriers with pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2021;19(4):469-473.

109. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317-327.

110. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357;(6349):409-413.

111. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473-1481.

112. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267-277.

113. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395-2406.

114. Fromer MW, Hawthorne J, Philips P, et al. An improved staging system for locally advanced pancreatic cancer: a critical need in the multidisciplinary era. Ann Surg Oncol. 2021;[Epub ahead of print].

115. Abrams RA, Winter KA, Safran H, et al. Results of the NRG Oncology/RTOG 0848 adjuvant chemotherapy question: erlotinib+gemcitabine for resected cancer of the pancreatic head: a phase II randomized clinical trial. Am J Clin Oncol. 2020;43(3):173-179.

116. Patel SH, Katz MHG, Ahmad SA. The landmark series: preoperative therapy for pancreatic cancer. Ann Surg Oncol. 2021;28(8):4104-4129.

117. Fong ZV, Ferrone CR. Surgery after response to chemotherapy for locally advanced pancreatic ductal adenocarcinoma: a guide for management. J Natl Compr Canc Netw. 2021;19(4):459-467.

118. Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol. 2019;5:1020-1027.

119. van Roessel S, van Veldhuisen E, Klompmaker S, et al. Evaluation of adjuvant chemotherapy in patients with resected pancreatic cancer after neoadjuvant FOLFIRINOX treatment. JAMA Oncol. 2020;6(11):1733-1740.

120. White RR, Murphy JD, Martin RCG. The landmark series: locally advanced pancreatic cancer and ablative therapy options.Ann Surg Oncol. 2021;28(8):4173-4180.

121. Reyngold M, O'Reilly EM, Varghese AM, et al. Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer. JAMA Oncol. 2021;7(5):735-738.

122. Fernandez-del Castillo C, Jimenez RE, Murphy JE. Supportive Care of the Patient with Locally Advanced or Metastatic Exocrine Pancreatic Cancer. Available at Last accessed July 14, 2021.

123. Drewes AM, Campbell CM, Ceyhan GO, et al. Pain in pancreatic ductal adenocarcinoma: a multidisciplinary, international guideline for optimized management. Pancreatology. 2018;18:446-457.

124. Powell-Brett S, Pande R, Roberts KJ. Achieving "marginal gains" to optimise outcomes in resectable pancreatic cancer. Cancers. 2021;13:1669.

125. Society on Sarcopenia, Cachexia and Wasting Disorders. Cachexia. Available at Last accessed August 13, 2021.

126. Loprinzi CL, Jatoi A. Management of Cancer Anorexia/Cachexia. Available at Last accessed August 13, 2021.

127. Currow DC, Glare P, Louw S, et al. A randomised, double blind, placebo-controlled trial of megestrol acetate or dexamethasone in treating symptomatic anorexia in people with advanced cancer. Sci Rep. 2021;11(1):2421.

128. Hunter CN, Abdel-Aal HH, Elsherief WA, et al. Mirtazapine in cancer-associated anorexia and cachexia: a double-blind placebo-controlled randomized trial. J Pain Symptom Manage. 2021:3924(21):00369.

129. Mücke M, Weier M, Carter C, et al. Systematic review and meta-analysis of cannabinoids in palliative medicine. J Cachexia Sarcopenia Muscle. 2018;9(2):220-234.

130. Bonn-Miller MO, Sisley S, Riggs P, et al. The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: a randomized cross-over clinical trial. PLoS ONE. 2021;16(3):e0246990.

131. Roeland EJ, Bohlke K, Baracos VE, et al. Management of cancer cachexia: ASCO guideline. J Clin Oncol. 2020;38(21):2438-2453.

132. Forsmark CE, Tang G, Xu H, et al. The use of pancreatic enzyme replacement therapy in patients with a diagnosis of chronic pancreatitis and pancreatic cancer in the US is infrequent and inconsistent. Aliment Pharmacol Ther. 2020;51(10):958-967.

133. Casolino R, Braconi C, Malleo G, et al. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine.Ann Oncol. 2021;32(2):183-196.

  • Back to Course Home
  • Participation Instructions
    • Review the course material online or in print.
    • Complete the course evaluation.
    • Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.